GLP-1s by year and indication GLP-1s by indication and year GLP-1 pipeline FAQs On March 19, 2026, the FDA approved a new, high-dose semaglutide (Wegovy HD) injection (7.2 mg) for once-weekly, subcutaneous (SC) administration for weight reduction and long-term maintenance
Different methylation modifications of histones by CR, combined with different transcription factors, co-regulate aging-related protein expression, thereby delaying aging
If evidence breadth is the priority, NAC has an edge
GLP-1 stands for glucagon-like peptide-1 receptor agonist medications, usually administered in the form of a subcutaneous injection
KLOW contains those three plus KPV, a tripeptide with anti-inflammatory activity in mucosal tissue